Press Releases Ypsomed Group
Burgdorf - Ypsomed has a general policy not to comment on stock price developments or rumours. Due to a enquiries from investors and press representatives, however, Ypsomed considers it important to make the following statements:
- Ypsomed is aware that Novo Nordisk AIS has filed a US-lawsuit against Sanofi-Aventis regarding alleged infringement of a patent by the OptiClik pen system. Ypsomed does not currently possess detailed information with respect to this claim. Sanofi-Aventis SA, Paris, has in the meantime rejected Novo Nordisk's claims of infringement as unjustified.
- Ypsomed is also aware that Sanofi-Aventis has made a voluntary market recall of 4 batches of OptiClik pens in Japan. No other marketed OptiClik pens or other pen systems are affected by this recall. The issues which led to the recall are known and are being corrected working closely with Sanofi-Aventis and the Japanese authorities. The recall is not related to the above mentioned claim by Novo Nordisk.
- lt is not correct that the majority shareholder Willy Michel or the BV Holding AG have sold shares since the 12 months lock up period expired on 21st September, 2005. There is also currently no intention on their part to sell shares. Furthermore, no member of the Management Committee of the Ypsomed Group has sold shares since the lock up expired.